Uses Of Monoclonal Antibodies For The Treatment Of Non-Hodgkin Lymphoma

Monoclonal antibodies targeted to cancer-associated antigens have been approved by the U.S. Food and Drug Administration (FDA) for various uses in oncology. In some cases, these agents are used in settings outside of the approved label (ie, off-label use). This evidence review is limited to 3 CD20 antigen-directed monoclonal antibodies (rituximab, ofatumumab, and obinutuzumab) used for patients with non-Hodgkin lymphoma. Ibritumomab (Zevalin), which combines a CD20-directed antibody with a radioactive agent, and monoclonal antibodies that target other antigens besides CD20, are not addressed here.